VANCOUVER, Oct. 3 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX - News) today announced that it has completed recruitment of patients for its Phase 1 clinical trial evaluating PRX302 in males with benign prostatic hyperplasia (BPH) and reported positive interim data from this study. The findings to date indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity.
